Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2010-10-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 9 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 September 2010'. It contains detailed operational updates, licensing and IP information, research and development progress, corporate matters, and a consolidated statement of cash flows for the quarter. The presence of substantive financial data such as cash flows and operational metrics for a specific quarter indicates this is a comprehensive interim financial report. The document is about a quarter period, not a full fiscal year, and includes financial statements and analysis, which fits the definition of an Interim / Quarterly Report (IR). It is not a brief announcement or a report publication notice, nor is it a full annual report or earnings release. Therefore, the correct classification is IR with high confidence. Q1 2011
2010-10-27 English
Validation of BREVAGen in Journal of NCI 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated October 28, 2010, from Genetic Technologies Limited. It discusses the validation of their BREVAGen genetic test for breast cancer risk, referencing published studies in the Journal of the National Cancer Institute and Journal of Clinical Oncology. The content focuses on scientific validation, clinical study results, and future plans for product launch. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a detailed announcement of scientific and product validation results rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a corporate announcement about a scientific validation and product update, which aligns best with a general Regulatory Filing (RNS) as a miscellaneous announcement that does not fit other categories.
2010-10-27 English
Presentation 5 pages ?Kb
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated October 18, 2010, presenting a detailed investor presentation by the CEO of Genetic Technologies Limited. It includes company highlights, business strategy, product information, market focus, and financial snapshot. The content is structured as a presentation with slides and speaker notes, typical of investor presentations. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is not a brief announcement or a regulatory filing but a detailed presentation aimed at investors and stakeholders. Therefore, the most appropriate classification is Investor Presentation (IP).
2010-10-17 English
Annual Report to shareholders 101 pages ?Kb
Annual Report Classification · 100% confidence The document is titled '2010 Annual Report and Notice of Annual General Meeting' and is an ASX announcement dated October 15, 2010. It explicitly states it is releasing the 2010 Annual Report and the Notice for the Annual General Meeting. The content includes detailed sections typical of an annual report such as business overview, strategy, financial summaries, directors' report, corporate governance statement, financial statements, auditor's report, and other comprehensive information. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or notice. Therefore, this document is the actual Annual Report for the fiscal year 2010. FY 2010
2010-10-14 English
Expiry of options 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated October 12, 2010, regarding the forfeiture and expiry of employee stock options. It provides details about the number of options forfeited or expired, their exercise prices, and expiry dates. The document is short (1203 characters) and focuses on a specific capital-related event involving options cancellation. There is no indication of financial statements, management discussion, or regulatory certifications. This fits the category of a capital or financing update related to changes in the company's capital structure due to option forfeiture/expiry. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2010-10-11 English
Full Year Statutory Accounts 65 pages ?Kb
Regulatory Filings
2010-09-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.